Royal Bank of Canada
CRDL

Royal Bank of Canada’s Cardiol Therapeutics CRDL Stock Holding History

Royal Bank of Canada’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29K Buy
21,648
+8,306
+62% +$8.52K ﹤0.01% 5738
2025
Q4 		$13K Buy
13,342
+892
+7% +$934 ﹤0.01% 6275
2025
Q3 		$13K Sell
12,450
-7,854
-39% -$9.53K ﹤0.01% 6378
2025
Q2 		$28K Buy
20,304
+7,490
+58% +$8.72K ﹤0.01% 6148
2025
Q1 		$12K Sell
12,814
-11,987
-48% -$14.7K ﹤0.01% 6086
2024
Q4 		$32K Buy
24,801
+671
+3% +$1.13K ﹤0.01% 5896
2024
Q3 		$48K Sell
24,130
-2,975
-11% -$6.17K ﹤0.01% 5715
2024
Q2 		$55K Buy
27,105
+10,676
+65% +$22.7K ﹤0.01% 5599
2024
Q1 		$31K Sell
16,429
-17,678
-52% -$23.8K ﹤0.01% 5726
2023
Q4 		$28K Sell
34,107
-10,342
-23% -$8.79K ﹤0.01% 6203
2023
Q3 		$40K Buy
44,449
+5,728
+15% +$5.47K ﹤0.01% 5890
2023
Q2 		$34K Sell
38,721
-13,905
-26% -$9.18K ﹤0.01% 5952
2023
Q1 		$25K Buy
52,626
+26,475
+101% +$15.7K ﹤0.01% 5938
2022
Q4 		$13K Sell
26,151
-3,288
-11% -$2K ﹤0.01% 6442
2022
Q3 		$30K Buy
29,439
+6,125
+26% +$7.47K ﹤0.01% 5974
2022
Q2 		$31K Sell
23,314
-11,900
-34% -$16.9K ﹤0.01% 5920
2022
Q1 		$54K Buy
35,214
+14,020
+66% +$23.1K ﹤0.01% 6032
2021
Q4 		$39K Buy
21,194
+6,999
+49% +$19.3K ﹤0.01% 6509
2021
Q3 		$59K Buy
+14,195
New +$51.4K ﹤0.01% 6064

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada's CRDL Position: Q1 2026 in Review

Royal Bank of Canada increased its Cardiol Therapeutics (CRDL) stake by 62% in Q1 2026, buying an estimated $8.52K and bringing the position to 21,648 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #5738.

Royal Bank of Canada first reported a position in CRDL in Q3 2021 and has held it in 19 quarters since. The position peaked at $59K in Q3 2021. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Royal Bank of Canada held 21,648 shares of Cardiol Therapeutics worth $29K as of Q1 2026.
  • Royal Bank of Canada bought 8,306 Cardiol Therapeutics shares in Q1 2026, an estimated $8.52K.
  • Cardiol Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5738 holding.
  • Royal Bank of Canada first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Royal Bank of Canada's Cardiol Therapeutics position peaked at $59K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.